Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study
Maintenance pemetrexed was associated with significantly prolonged median progression‑free survival (15.5 vs. 7.9 months; p < 0.001) and overall survival (22.3 vs. 16.4 months; p = 0.002) compared with observation.
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor prognosis, and the role of maintenance therapy after first‑line platinum‑pemetrexed chemotherapy remains unclear. We conducted a multicenter retrospective study including 96 patients with metastatic or unresectable MPM treated across eight tertiary oncology centers. Eligible patients had received at least four cycles of first‑line platinum‑pemetrexed and achieved disease control, after which they were either administered maintenance pemetrexed (n = 54) or observed without further treatment (n = 42). Maintenance pemetrexed was associated with significantly prolonged median progression‑free survival (15.5 vs 7.9 months; p < 0.001) and overall survival (22.3 vs 16.4 months; p = 0.002) compared with observation.
The study provides real‐world evidence that continuing pemetrexed as maintenance therapy after initial platinum‑pemetrexed treatment improves both progression‑free survival and overall survival in patients with malignant pleural mesothelioma.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma